Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies for genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases. Pairing Roche’s long-standing commitment to developing medicines in hemophilia with Spark Therapeutics’ proven gene therapy expertise brings together the best team of collaborators researching gene therapies in hemophilia A as part of our endeavor to create additional benefit beyond current treatment options.